Abstract
Abstract Objective Glycemic outcomes in youth with type 1 diabetes (T1D) in the United States using the two most common automated insulin delivery (AID) systems, Insulet Omnipod 5 (OP5) and Tandem Control IQ (CIQ), have not been compared. We performed the first head-to-head analysis of changes in glycemic metrics among youth initiating AID. Methods This single center, retrospective study included youth <21 years with T1D, who started OP5 or CIQ between 1/2020 and 12/2023, and had ≥70% CGM active time. 14-day baseline and 90-day CGM and AID data were obtained. A multiple linear regression model assessed for changes in 90-day time in range (TIR) according to AID system, adjusting for covariates. Sub-analyses were conducted according to baseline TIR categories. Results Among the 428 youth included, there were 214 (50%) in each AID group. OP5 users had a shorter T1D duration (1.6 vs 5.5 years, p<0.001) and were more likely to have transitioned from multiple daily injections (76.1% vs 20.1%, p<0.001). Baseline TIR was similar between groups (OP5 51.6% vs CIQ 53.1%, p=0.70). 90-day TIR increased in both groups (p<0.001), rising by 11.8%-points (95% CI[10.4,13.3]) in OP5 users and 9.8%-points (95% CI[8.3,11.2]) in CIQ users, without any significant between group differences (p=0.08). There were no between group differences in 90-day TIR according to categorical baseline TIR. Conclusions There are no clinically significant differences in 90-day TIR among youth with T1D initiating the two most commonly used AID systems. Patient preference and shared decision making should continue to guide the selection of AID systems.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call